ShangPharma Corp. (SHP) Misses Q4 EPS by 4c; Issues Light FY12 Revs Outlook

ShangPharma Corp. (NYSE: SHP) reported Q4 EPS of $0.21, $0.04 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $30.5 million versus the consensus estimate of $31.8 million.

Sees FY2012 revenue of $131.7-$136.2 million, versus the consensus of $140.03 million.

For earnings history and earnings-related data on ShangPharma Corp. (SHP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'